ES8701683A1 - Un procedimiento para la preparacion de una composicion terapeutica que contiene un fosfato de dialquilo. - Google Patents

Un procedimiento para la preparacion de una composicion terapeutica que contiene un fosfato de dialquilo.

Info

Publication number
ES8701683A1
ES8701683A1 ES547738A ES547738A ES8701683A1 ES 8701683 A1 ES8701683 A1 ES 8701683A1 ES 547738 A ES547738 A ES 547738A ES 547738 A ES547738 A ES 547738A ES 8701683 A1 ES8701683 A1 ES 8701683A1
Authority
ES
Spain
Prior art keywords
independently represent
external application
medical composition
carbon atoms
hydrocarbon group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES547738A
Other languages
English (en)
Spanish (es)
Other versions
ES547738A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Publication of ES547738A0 publication Critical patent/ES547738A0/es
Publication of ES8701683A1 publication Critical patent/ES8701683A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES547738A 1984-10-11 1985-10-09 Un procedimiento para la preparacion de una composicion terapeutica que contiene un fosfato de dialquilo. Expired ES8701683A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59213152A JPS6191137A (ja) 1984-10-11 1984-10-11 外用薬剤組成物

Publications (2)

Publication Number Publication Date
ES547738A0 ES547738A0 (es) 1986-12-01
ES8701683A1 true ES8701683A1 (es) 1986-12-01

Family

ID=16634426

Family Applications (1)

Application Number Title Priority Date Filing Date
ES547738A Expired ES8701683A1 (es) 1984-10-11 1985-10-09 Un procedimiento para la preparacion de una composicion terapeutica que contiene un fosfato de dialquilo.

Country Status (7)

Country Link
US (1) US4686211A (enExample)
EP (1) EP0179277B1 (enExample)
JP (1) JPS6191137A (enExample)
DE (1) DE3565937D1 (enExample)
ES (1) ES8701683A1 (enExample)
HK (1) HK33691A (enExample)
MY (1) MY100022A (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01151516A (ja) * 1987-12-08 1989-06-14 Shionogi & Co Ltd ビタミンｅ配合外用剤
GB8828014D0 (en) * 1988-12-01 1989-01-05 Unilever Plc Topical composition
GB8828020D0 (en) * 1988-12-01 1989-01-05 Unilever Plc Topical composition
GB8828013D0 (en) * 1988-12-01 1989-01-05 Unilever Plc Topical composition
GB8828017D0 (en) * 1988-12-01 1989-01-05 Unilever Plc Topical composition
GB8828018D0 (en) * 1988-12-01 1989-01-05 Unilever Plc Topical composition
US4906454A (en) * 1989-02-23 1990-03-06 The Procter & Gamble Company Deodorant compositions containing specific piroctone salts and perfumes
US5262165A (en) * 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
GB9003199D0 (en) * 1990-02-13 1990-04-11 Unilever Plc Topical composition
US5565207A (en) * 1990-09-19 1996-10-15 Pola Kasei Kogyo Kabushiki Kaisha Scalp moisturizer and external skin preparation
GB9101986D0 (en) * 1991-01-30 1991-03-13 Smith & Nephew Pharmaceutical compositions
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
TW251302B (enExample) * 1992-12-28 1995-07-11 Kao Corp
US5665742A (en) * 1994-05-31 1997-09-09 Kao Corporation Bath medicine composition and its use in inhibiting the generation of body odor
US5968983A (en) 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US5543430A (en) * 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
US6239172B1 (en) * 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5560913A (en) * 1995-01-27 1996-10-01 The Procter & Gamble Company Pharmaceutical compositions
US6605751B1 (en) * 1997-11-14 2003-08-12 Acrymed Silver-containing compositions, devices and methods for making
WO1999039575A2 (en) * 1998-02-09 1999-08-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Synergistic biocidal activity of ternary complexes of negatively -charged biocides (component a), transition metal ions (component b), and neutral chelators (component c)
US5972920A (en) * 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
US6121253A (en) * 1998-11-20 2000-09-19 Merck Frosst Canada & Co. Prostaglandin conjugates for treating or preventing bone disease
US6254294B1 (en) * 1999-08-09 2001-07-03 Sigrid G. Muhar Pharmaceutical kit
FR2799369B1 (fr) * 1999-10-08 2001-12-21 Oreal Association d'escine et de sulfate de dextran et son utilisation
DE60028415T2 (de) 1999-12-30 2007-06-06 Acrymed, Portland Methode und zusammensetzungen für verbesserte abgabevorrichtungen
US7758888B2 (en) * 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
BRPI0115953B8 (pt) * 2000-11-14 2021-05-25 Vital Health Sciences Pty Ltd complexos de derivados de fosfato
EP1254909A1 (de) * 2001-04-30 2002-11-06 Cognis Iberia, S.L. Phosphorsäureester
JP4745608B2 (ja) * 2001-07-27 2011-08-10 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 電子伝達剤のリン酸誘導体を用いた皮膚治療
WO2003049774A1 (en) * 2001-12-13 2003-06-19 Vital Health Sciences Pty Ltd Transdermal transport of compounds
US6833139B1 (en) * 2002-01-09 2004-12-21 Ferndale Laboratories, Inc. Composition and method for the treatment of anorectal disorders
US8486426B2 (en) * 2002-07-29 2013-07-16 Kimberly-Clark Worldwide, Inc. Methods and compositions for treatment of dermal conditions
AU2002950713A0 (en) * 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
BRPI0406484A (pt) * 2003-01-17 2005-12-06 Vital Health Sciences Pty Ltd Método de inibição da ocorrência de uma ou mais das seguintes condições: a proliferação de monócitos/macrófagos; ou a proliferação de células do músculo liso; ou a expressão de receptores de cd36; ou a absorção de lipoproteìna de baixa densidade - ldl oxidada, método de alìvio de sintomas de tratamento ou prevenção de aterosclerose; de diabetes; do mal de alzheimer, método de inibição da ocorrência da formação de placas no sistema vascular, método de alìvio da inflamação associada a ocorrência de uma ou de mais das seguintes condições: a proliferação de monócitos, a proliferação de células do músculo liso, a expressão de ldl oxidadas ou de receptor descontaminante, composição farmacêutica, uso de uma quantidade eficaz de um ou mais derivados ou fosfato de um ou mais agentes de transferência de elétrons conjuntamente com um veìculo ou um diluente apropriado, uso de uma quantidade eficaz de um ou mais derivados de fosfato de (alfa)-tocoferol conjuntamente com um veìculo ou um diluente apropriado e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons selecionados do grupo que consiste em fosfato mono-tocoferila, fosfato de di-tocoferila e as misturas destes conjuntamente com um veìculo ou um diluente apropriado
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
AU2005202477B2 (en) * 2004-03-03 2005-12-15 Vital Health Sciences Pty Ltd Alkaloid formulations
US20050282870A1 (en) * 2004-06-16 2005-12-22 Carter Stephen G Peripherally-acting vasodilators
US8361553B2 (en) 2004-07-30 2013-01-29 Kimberly-Clark Worldwide, Inc. Methods and compositions for metal nanoparticle treated surfaces
CN101010003B (zh) 2004-07-30 2012-07-04 金佰利-克拉克国际公司 抗微生物的银组合物
WO2006015317A2 (en) * 2004-07-30 2006-02-09 Acrymed, Inc. Antimicrobial devices and compositions
WO2006034249A2 (en) * 2004-09-20 2006-03-30 Acrymed, Inc. Antimicrobial amorphous compositions
US20090233881A1 (en) * 2005-03-03 2009-09-17 Vital Health Sciences Pty. Ltd Compounds having anti-cancer properties
ES2557475T3 (es) * 2005-06-17 2016-01-26 Vital Health Sciences Pty Ltd. Un portador que comprende uno o más derivados di- y/o monofosfato de agentes de transferencia de electrones
KR101158162B1 (ko) 2005-08-02 2012-06-19 솔-겔 테크놀로지스 리미티드 수 불용성 성분을 금속 산화물로 피복시키는 방법
EP1973547A1 (en) * 2005-12-23 2008-10-01 Vital Health Sciences Pty Ltd. Compounds having cytokine modulating properties
EP2015722B1 (en) * 2006-04-28 2016-11-16 Avent, Inc. Antimicrobial site dressings
ES2763829T3 (es) 2007-02-01 2020-06-01 Sol Gel Tech Ltd Método para preparar partículas que comprenden un revestimiento de óxido de metal
JP2010517996A (ja) 2007-02-01 2010-05-27 ソル − ゲル テクノロジーズ リミテッド 過酸化物及びレチノイドを含む局所適用用組成物
JP2010235523A (ja) * 2009-03-31 2010-10-21 Kao Corp 水性毛髪洗浄剤
EP2531047B1 (en) 2010-02-05 2024-11-13 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
WO2011120084A1 (en) 2010-03-30 2011-10-06 Phosphagenics Limited Transdermal delivery patch
EP2685992A4 (en) 2011-03-15 2014-09-10 Phosphagenics Ltd AMINOCHINOLINE AS A KINASEHEMMER
US9687465B2 (en) 2012-11-27 2017-06-27 Sol-Gel Technologies Ltd. Compositions for the treatment of rosacea
JP6882321B2 (ja) 2015-12-09 2021-06-02 フォスファージニクス リミテッド 医薬製剤
IL267006B2 (en) 2016-12-21 2024-11-01 Phosphagenics Ltd Process for phosphorylation of a complex alcohol with p4o10 at high temperatures, and products thereof
HRP20251185T1 (hr) 2017-07-12 2025-11-21 Sol-Gel Technologies Ltd. Tvari koje obuhvaćaju tretinoin u kapsulama
JP2019043853A (ja) * 2017-08-30 2019-03-22 旭化成株式会社 経皮吸収促進剤、経皮吸収促進助剤、及び経皮製剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046886A (en) * 1975-01-17 1977-09-06 The Procter & Gamble Company Dermatological compositions
US4130667A (en) * 1976-01-12 1978-12-19 The Procter & Gamble Company Dermatological compositions

Also Published As

Publication number Publication date
EP0179277B1 (en) 1988-11-02
US4686211A (en) 1987-08-11
JPH0469129B2 (enExample) 1992-11-05
ES547738A0 (es) 1986-12-01
HK33691A (en) 1991-05-10
DE3565937D1 (en) 1988-12-08
JPS6191137A (ja) 1986-05-09
MY100022A (en) 1989-04-20
EP0179277A1 (en) 1986-04-30

Similar Documents

Publication Publication Date Title
ES8701683A1 (es) Un procedimiento para la preparacion de una composicion terapeutica que contiene un fosfato de dialquilo.
HUP9600448A2 (hu) Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk
ES8507130A1 (es) Procedimiento para preparar derivados de piperazina
DE10199023I2 (de) Benzoenaphthalinderivate Verfahren zu deren Herstellung und ihre Verwendung in Pharmazie und Kosmetik
NO170280C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfamatderivater
EP0147361A3 (en) 11-beta-aryl-estradienes, their preparation and pharmaceutical compositions containing them
MD1900B2 (en) Aerosolic pharmaceutical composition and method of treatment of respiratory affections
GB8328073D0 (en) Chemical compounds
EP0034473A3 (en) Substituted imidazoles, their preparation, pharmaceutical compositions containing the same and their use in therapy
AU4272696A (en) Non-beta-oxidizable fatty acid analogues, their uses as therpeutic active medicaments, and preparation thereof
AUPO111096A0 (en) New compound
IL87894A0 (en) Androstane 17-carboxylic acid esters,their preparation and pharmaceutical compositions containing them
ES8400427A1 (es) Un procedimiento para la preparacion de nuevos derivados de 2-piperazino pirimidina.
DE3476847D1 (en) A remedial or prophylactic agent for the treatment of seizures
ES2005504A6 (es) Un procedimiento para preparar nuevos derivados de tetrahidrofurano.
ES476645A1 (es) Procedimiento para la obtencion de derivados aminados de pi-razol (1,5-a)s troazina.
ES8403857A1 (es) Procedimiento de preparacion de dederivados de amino-2--tetrahidro-1 2 3 4-naftaleno
ES472085A1 (es) Un procedimiento para la preparacion de una composicion te- rapeutica para el tratamiento de enfermedades alergicas.
ES8100249A1 (es) Un metodo para la preparacion de un compuesto de acido hi- droxamico
TNSN91055A1 (fr) Nouvelles tetrahydroimidazo (1,4) benzodiazepine -2-(thi) ones
HUT41025A (en) Process for preparing octahydro-indolizine derivatives and pharmaceutical compositions containing such compounds as active ingredients
AU560542B2 (en) Pyridazine derivatives which have c.n.s. activity
KR950702412A (ko) 항 hiv제
ES481603A1 (es) Un procedimiento para la preparacion de un derivado de la hidantoina.
IL134038A0 (en) Polyhydroxyalkylpyrazine derivatives, their preparation and medicines containing them